The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-fl ight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
PLASMA PROTEASE C1 BIOPOLYMER MARKERS PREDICTIVE OF ALZHEIMERS DISEASE